In our previous study, sulfisoxazole and macitentan, which target endothelin receptor A, inhibited the secretion of tumor-derived EV PD-L1, but not the expression of cellular PD-L1, by regulating EV secretion in breast cancer cells and mouse models [18,20,35]. This evidence concerns the gene CD274 and breast carcinoma.